Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 4/20 | 0.44 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.38 |
| ▸ | TK1 | P04183 | 2/20 | 0.35 |
| ▸ | TK2 | O00142 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.33 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23635267 | 1.00 | OGA (0.44) | OGASLC5A2TK1TK2PDE4D | |
| SCHEMBL13471607 | 1.00 | OGA (0.44) | OGASLC5A2TK1TK2PDE4D | |
| SCHEMBL12694172 | 0.88 | OGA (0.41) | OGASLC5A2TK1PDE4DPIM1 | |
| SCHEMBL20154818 | 0.88 | OGA (0.41) | OGASLC5A2TK1PDE4DPIM1 | |
| SCHEMBL23635993 | 0.84 | OGA (0.40) | OGASLC5A2TK1TK2PDE4D | |
| SCHEMBL24760374 | 0.81 | OGA (0.39) | OGASLC5A2TK1TK2PDE4D | |
| SCHEMBL16556942 | 0.81 | OGA (0.39) | OGASLC5A2TK1TK2PDE4D | |
| SCHEMBL24943578 | 0.81 | OGA (0.39) | OGASLC5A2TK1TK2PDE4D | |
| SCHEMBL21096516 | 0.81 | OGA (0.33) | OGA | |
| SCHEMBL22065208 | 0.81 | OGA (0.39) | OGASLC5A2TK1TK2PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160199328-A1 | INTERMEDIATE METABOLISM PRODUCTS TO POTENTIATE AMINOGLYCOSIDE ANTIBIOTICS IN BACTERIAL INFECTIONS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2016-07-14 | — | — | US | disclosed |
| US-20150366889-A1 | PROTON-MOTIVE FORCE STIMULATION TO POTENTIATE AMINOGLYCOSIDE ANTIBIOTICS AGAINST PERSISTENT BACTERIA | TRUSTEES OF BOSTON UNIVERSITY (US) | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150366889-A1 | PROTON-MOTIVE FORCE STIMULATION TO POTENTIATE AMINOGLYCOSIDE ANTIBIOTICS AGAINST PERSISTENT BACTERIA | ATP5ME, ATP6V1E1, ATF4 | OGA 1098/4885SLC5A2 1944/4885TK1 3161/4885 |
| US-20160199328-A1 | INTERMEDIATE METABOLISM PRODUCTS TO POTENTIATE AMINOGLYCOSIDE ANTIBIOTICS IN BACTERIAL INFECTIONS | HAMP, TIMM50, ATF4 | OGA 390/4885SLC5A2 1647/4885TK1 2683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.